Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Novel strategies for treating relapsed/refractory urothelial carcinoma.

Literature DB >> 21110758

Novel strategies for treating relapsed/refractory urothelial carcinoma.

Gopa Iyer¹, Matthew I Milowsky, Dean F Bajorin.

Abstract

Advanced urothelial cancer is associated with a poor prognosis and there has been no substantial progress over the past three decades since the development of platinum-based multiagent chemotherapy. Clinical trials evaluating novel agents and combinations including chemotherapeutic drugs, as well as targeted inhibitors, are desperately needed. With a better understanding of the complex molecular alterations that drive urothelial tumorigenesis, new targets for novel therapeutics are being defined. This article will describe the current state of advanced urothelial cancer treatment and provide a comprehensive discussion of novel agents in development.

Entities: CellLine Chemical Disease Gene Species

Mesh：

Year: 2010 PMID： 21110758 PMCID： PMC3705930 DOI： 10.1586/era.10.182

Source DB: PubMed Journal: Expert Rev Anticancer Ther ISSN： 1473-7140 Impact factor: 4.512

120 in total

1. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma.

Authors: J A McCaffrey; S Hilton; M Mazumdar; S Sadan; W K Kelly; H I Scher; D F Bajorin
Journal: J Clin Oncol Date: 1997-05 Impact factor: 44.544

2. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors.

Authors: C Billerey; D Chopin; M H Aubriot-Lorton; D Ricol; S Gil Diez de Medina; B Van Rhijn; M P Bralet; M A Lefrere-Belda; J B Lahaye; C C Abbou; J Bonaventure; E S Zafrani; T van der Kwast; J P Thiery; F Radvanyi
Journal: Am J Pathol Date: 2001-06 Impact factor: 4.307

3. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma.

Authors: Adel H Jebar; Carolyn D Hurst; Darren C Tomlinson; Colin Johnston; Claire F Taylor; Margaret A Knowles
Journal: Oncogene Date: 2005-08-04 Impact factor: 9.867

Review 4. Molecular pathogenesis of bladder cancer.

Authors: Margaret A Knowles
Journal: Int J Clin Oncol Date: 2008-08-15 Impact factor: 3.402

5. Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model.

Authors: Guru Sonpavde; Weiguo Jian; Hao Liu; Meng-Fen Wu; Steven S Shen; Seth P Lerner
Journal: Urol Oncol Date: 2008-06-04 Impact factor: 3.498

6. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors: Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal: N Engl J Med Date: 2004-06-03 Impact factor: 91.245

Review 7. Maintenance therapy in nonsmall-cell lung cancer: a new treatment paradigm.

Authors: Tony S K Mok; Suresh S Ramalingam
Journal: Cancer Date: 2009-11-15 Impact factor: 6.860

8. Prognostic value of amplification of c-erb-B2 in bladder carcinoma.

Authors: U Lönn; S Lönn; S Friberg; B Nilsson; C Silfverswärd; B Stenkvist
Journal: Clin Cancer Res Date: 1995-10 Impact factor: 12.531

9. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group.

Authors: B J Roth; R Dreicer; L H Einhorn; D Neuberg; D H Johnson; J L Smith; G R Hudes; S M Schultz; P J Loehrer
Journal: J Clin Oncol Date: 1994-11 Impact factor: 44.544

5. Exploring the Molecular Mechanism of Tong Xie Yao Fang in Treating Ulcerative Colitis Using Network Pharmacology and Molecular Docking.

Authors: Menglong Zou; Ying Zhu
Journal: Evid Based Complement Alternat Med Date: 2022-09-27 Impact factor: 2.650

5 in total

Novel strategies for treating relapsed/refractory urothelial carcinoma.

1. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma.

2. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors.

3. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma.

Review 4. Molecular pathogenesis of bladder cancer.

5. Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model.

6. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Review 7. Maintenance therapy in nonsmall-cell lung cancer: a new treatment paradigm.

8. Prognostic value of amplification of c-erb-B2 in bladder carcinoma.

9. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group.

Review 10. Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer.

Review 1. Urothelial carcinoma of the bladder: definition, treatment and future efforts.

Review 2. Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet?

Review 3. Emerging critical role of molecular testing in diagnostic genitourinary pathology.

4. Inhibiting cytoplasmic accumulation of HuR synergizes genotoxic agents in urothelial carcinoma of the bladder.

5. Exploring the Molecular Mechanism of Tong Xie Yao Fang in Treating Ulcerative Colitis Using Network Pharmacology and Molecular Docking.